Agustin Arrieta, MD
Otolaryngology · Miami, FLNPI 1528052388
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $71,875 of the $94,597 with a category attached, or 76.0%. GSK accounts for 79.5% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $29,794, 8.1 times the $3,662 reported in 2019. Among otolaryngology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $271.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$75K
- Arthrex$6K
- Intersect ENT, Inc.$3K
- Johnson & Johnson$1K
- Aerin Medical Inc.$1K
- Medtronic$1K
- plus $6K from 22 others
What the payments were for
- Consulting fees$6,1256%
- Speaking & faculty fees$71,87576%
- Travel & lodging$3,5664%
- Food & beverage$12,89414%
- Education$1320%
- Gifts$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 109 | $75,248 |
| Arthrex | 6 | $6,224 |
| Intersect ENT, Inc. | 21 | $3,147 |
| Johnson & Johnson(2 entities) | 13 | $1,332 |
| Aerin Medical Inc. | 33 | $1,261 |
| Medtronic(2 entities) | 22 | $1,228 |
| Sanofi | 36 | $1,136 |
| Medical Device Business Services, Inc. | 7 | $993 |
| Neurent Medical Limited | 6 | $720 |
| Regeneron Healthcare Solutions, Inc. | 29 | $683 |
| Optinose US, Inc. | 26 | $579 |
| Acclarent, Inc | 10 | $456 |
| Inspire Medical Systems, Inc. | 2 | $364 |
| KARL Storz Endoscopy-america | 3 | $246 |
| Hill Dermaceuticals, Inc. | 1 | $224 |
| Amgen(2 entities) | 5 | $214 |
| Smith+Nephew | 6 | $174 |
| Integra Lifesciences Corporation | 2 | $122 |
| GT Metabolic Solutions Inc | 1 | $56 |
| Stryker | 2 | $42 |
| Cook Medical LLC | 2 | $27 |
| Siemens Medical Solutions USA, Inc. | 1 | $21 |
| Novartis | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Aroa Biosurgery Incorporated | 1 | $16 |
| Kaleo, Inc. | 1 | $14 |
| Alk-abello, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$74,037
- PROPEL$3,104
- SINUVA$2,346
- Monarch Platform$952
- VIVAER STYLUS$723
- RHINAER STYLUS$723
- NEUROMARK Device$646
- NEUROMARK Radiofrequency Console$646
- Tolak$224
- Inspire Upper Airway Stimulation System$203
- Inspire$161
- VivAer$157
- RhinAer$157
- DUPIXENT$126
- KRYSTEXXA$124
- TruDi Nav Cable$116
- NUVENT$113
- TELESCOPE, HOPKINS II FORWARD OBLIQUE$113
- Xhance$111
How this compares
$94,597 in reported general payments places this provider in the 95th percentile of 586 otolaryngology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 30 | $124,242 |
| NucalaMepolizumab | 12 | $50,806 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $27,952 |
| Azelastine Hcl | 924 | $25,233 |
| XhanceFluticasone Propionate | 22 | $13,845 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 131 | $12,113 |
| Ipratropium Bromide | 580 | $9,271 |
| Fluocinolone Acetonide | 161 | $6,785 |
| RyaltrisOlopatadine Hcl/Mometasone | 25 | $6,736 |
| Fluticasone Propionate | 236 | $4,212 |
| Famotidine | 176 | $2,403 |
| Levocetirizine Dihydrochloride | 251 | $2,262 |
| Epinephrine | 15 | $1,835 |
| Fluocinolone Acetonide Oil | 21 | $1,585 |
| Clarithromycin | 90 | $1,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta | $75,248 | $78,75853 claims |
| Optinose US, Inc.Xhance | $579 | $13,84522 claims |
| Hikma Pharmaceuticals USARyaltris, Epinephrine | $19 | $8,57140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 otolaryngology providers in Florida.
Other otolaryngology in Miami
- Maria SuurnaMiami$189K
- Francisco PernasMiami$70K
- Adrien EshraghiMiami$41K
- Michael HofferMiami$24K
- Corinna LevineMiami$16K
- Jason LeibowitzMiami$13K
- Donald WeedMiami$8K
- Cecelia DamaskOrlando$707K
- Ralph TufanoSarasota$469K
- Franklin RimellFort Myers$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.